Japan Approves Continued Use Of Strattera For AD/HD Patients Over 18
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare June 15 notified Eli Lilly's Japan subsidiary it expanded labeling for Strattera (atomoxetine), allowing the drug to be used continuously for patients over 18 years. Currently, Strattera is indicated for attention-deficit hyperactivity disorder for patients aged 6 to 18. However, the change only applies to patients who have started taking the drug before the age of 18 and need to continue the treatment. Eli Lilly is conducting a Phase III trial of Strattera on adult patients. Many AD/HD patients in Japan have expressed a desire to continue the medication even after they turn 18. (Click here for more - Japanese language)
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.